Up Day as Wall Stre...
Health Care: Drugs
AbbVie Inc (ABBV: NYSE)
$43.01 -0.20 | -0.46%
06/17/13 - 04:00 PM ET
3.42M / 6.29M
Vol / Avg. Vol:43.40 / 43.21
Open / Prev. Close:42.68 - 43.50
Today's Range:32.51 - 48.00
52 Wk Range:26.49%
Performance YTD:TheStreet Rating:
Portfolios with ABBV
- Portfolio NameUser Type
- UserDC
- ContributorStocks Fund Managers Love Q...
- UserCapt Jer
- UserGlobo Gym Investments
Latest ABBV Headlines from TheStreet
- 5 Stocks Fund Managers Love for 2013 04.17.13 | 11:04 am
- Astra, Rigel Arthritis Pill Posts Mixed Trial Results 04.05.13 | 05:04 am
- Repros CEO: My Testosterone Drug Helped Gay Cubans Have Lots of Sex 03.28.13 | 12:03 pm
- Cramer's 'Mad Money' Recap: The Apple of My Eye 02.07.13 | 08:02 pm
- Cramer's 6 Stocks in 60 Seconds: ABBV MGM DNKN K FIVE MJN 01.16.13 | 10:01 am
- Cramer's Top Stock Picks: ABT ABBV LPI DELL 01.16.13 | 06:01 am
- Cramer's 'Mad Money' Recap: A Slumbering Market 01.15.13 | 08:01 pm
- The Many Reasons to Still Own Abbott Labs 01.04.13 | 06:01 am
- Stocks Skid as Republicans' 'Fiscal-Cliff' Plan Hits Dead End 12.21.12 | 02:12 pm
Press Releases for ABBV
- Sofia Vergara Encourages Individuals With Hypothyroidism To "Follow The Script" - PR Newswire 04.17.13 | 12:04 pm
- AbbVie To Host First-Quarter Earnings Conference Call - PR Newswire 04.08.13 | 09:04 am
- Receptos Licenses Anti-Interleukin-13 Antibody From AbbVie For Phase 2 Development In Orphan Disease - PR Newswire 03.13.13 | 08:03 am
- AbbVie To Present At Barclays Global Health Care Conference - PR Newswire 02.27.13 | 09:02 am
- AbbVie To Present At Cowen And Company 33rd Annual Health Care Conference - PR Newswire 02.20.13 | 09:02 am
- AbbVie Declares Dividend And Announces Share Repurchase Program - PR Newswire 02.15.13 | 09:02 am
- AbbVie Named To S&P 500 Dividend Aristocrat Index - PR Newswire 01.21.13 | 09:01 am
- Abbott And AbbVie Announce Investor Calls - PR Newswire 01.14.13 | 09:01 am
- AbbVie Declares Inaugural Dividend - PR Newswire 01.04.13 | 05:01 pm
Partner Headlines for ABBV
- Bristol-Myers Squibb, AbbVie Announce Progression-Free Survival Data from Phase 2 Multiple Myeloma Study - Benzinga 06.15.13 | 11:06 am
- Abbott Progresses with Absorb in Japan - Analyst Blog - Zacks 06.14.13 | 11:06 pm
- UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential - Benzinga 06.07.13 | 12:06 pm
- CE Mark for Abbott's Xience Xpedition 48 - Analyst Blog - Zacks 05.23.13 | 12:05 am
- Positive Data on Roche Candidate - Analyst Blog - Zacks 05.22.13 | 11:05 pm
- US doctors paid $1bn by top drug companies - Financial Times 05.22.13 | 07:05 pm
- Santarus Earnings Trounce Estimates; Stock Hits High - Investor's Business Daily 05.06.13 | 05:05 pm
- Gilead's HCV Drug Pipeline Outshines Weak Q1 Results - Investor's Business Daily 05.02.13 | 06:05 pm
- Top Fund Buys Focus On Defensive Stocks, Housing - Investor's Business Daily 05.02.13 | 05:05 pm
- Apple cleans up with $17bn US bond issue - Financial Times 04.30.13 | 10:04 pm
